1. Indications:

Ventax (Venetoclax) 100 mg is indicated for the treatment of:

• Chronic lymphocytic leukemia (CLL) in adult patients who have received at least one prior therapy.
• Acute myeloid leukemia (AML) in adult patients who are 75 years old or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.

2. Pharmacology:

Ventax (Venetoclax) 100 mg exerts its pharmacological effects by selectively inhibiting the activity of the BCL-2 protein. By blocking BCL-2, Venetoclax promotes apoptosis (programmed cell death) in cancer cells, particularly those with overexpression of BCL-2, such as CLL and AML cells.

3. Dosage and Administration:

The recommended dosage of Ventax (Venetoclax) 100 mg may vary depending on individual patient characteristics and treatment regimen. Typically, the prescribed dose is 100 mg taken orally once daily, with or without food. Treatment duration and dose adjustments may vary based on the response to therapy and the discretion of the treating healthcare provider.

4. Interaction:

Ventax (Venetoclax) 100 mg may interact with other medications, including:

• Strong CYP3A inhibitors or inducers: Co-administration with drugs that affect CYP3A metabolism may alter the plasma concentration of Venetoclax.
• Drugs that are substrates of organic cation transporter 2 (OCT2) or multidrug and toxin extrusion protein 1 (MATE1): Co-administration with OCT2 or MATE1 substrates may alter the plasma concentration of Venetoclax.

Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to avoid potential interactions.

5. Side Effects:

Common side effects associated with Ventax (Venetoclax) 100 mg may include:

• Neutropenia (low white blood cell count)
• Thrombocytopenia (low platelet count)
• Anemia
• Nausea
• Diarrhea
• Fatigue

Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before using Ventax (Venetoclax) 100 mg, patients should be aware of the following precautions:

• Tumor lysis syndrome (TLS), including fatal cases, has been reported with Venetoclax. Patients should be closely monitored for signs and symptoms of TLS during treatment initiation and subsequent dose escalation.
• Ventax may cause fetal harm if used during pregnancy. Female patients of reproductive potential should use effective contraception during treatment and for at least 30 days after the last dose.

7. Overdose Effects:

In case of overdose with Ventax (Venetoclax) 100 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Venetoclax overdose, and patients should seek immediate medical attention if overdose is suspected.